CY1122145T1 - Ανοσογονικη συνθεση για clostridium difficile - Google Patents

Ανοσογονικη συνθεση για clostridium difficile

Info

Publication number
CY1122145T1
CY1122145T1 CY20191101061T CY191101061T CY1122145T1 CY 1122145 T1 CY1122145 T1 CY 1122145T1 CY 20191101061 T CY20191101061 T CY 20191101061T CY 191101061 T CY191101061 T CY 191101061T CY 1122145 T1 CY1122145 T1 CY 1122145T1
Authority
CY
Cyprus
Prior art keywords
clostridium difficile
protein
cdtb
modify
binding domain
Prior art date
Application number
CY20191101061T
Other languages
English (en)
Inventor
Cindy Castado
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1411306.2A external-priority patent/GB201411306D0/en
Priority claimed from GB201411371A external-priority patent/GB201411371D0/en
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of CY1122145T1 publication Critical patent/CY1122145T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε ανοσογονικές συνθέσεις που περιλαμβάνουν απομονωμένη Clostridium difficile CDTb. Συγκεκριμένα, η απομονωθείσα Clostridium difficile CDTb πρωτεΐνη έχει υποστεί μετάλλαξη για τροποποίηση της ικανότητας σχηματισμού πόρου, τροποποίηση της ικανότητας επταμερισμού ή είναι ακρωτηριασμένη CDTb πρωτεΐνη με το πεπτίδιο-σήματος και το προπεδίο απομακρυνθέντα και επίσης το πεδίο σύνδεσης υποδοχέα απομακρυνθέν ή/και το πεδίο σύνδεσης CDTa απομακρυνθέν. Η εφεύρεση επίσης αφορά σε πρωτεΐνες σύντηξης που περιλαμβάνουν πρωτεΐνη CDTa και πρωτεΐνη CDTb. Εμβόλια που περιλαμβάνουν τέτοιες ανοσογονικές συνθέσεις και θεραπευτικές χρήσεις των ιδίων επίσης αποτελούν μέρος της εφεύρεσης.
CY20191101061T 2014-06-25 2019-10-09 Ανοσογονικη συνθεση για clostridium difficile CY1122145T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1411306.2A GB201411306D0 (en) 2014-06-25 2014-06-25 Immunogenic composition
GB201411371A GB201411371D0 (en) 2014-06-26 2014-06-26 Immunogenic composition
PCT/EP2015/064324 WO2015197737A1 (en) 2014-06-25 2015-06-25 Clostridium difficile immunogenic composition

Publications (1)

Publication Number Publication Date
CY1122145T1 true CY1122145T1 (el) 2020-11-25

Family

ID=53498986

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191101061T CY1122145T1 (el) 2014-06-25 2019-10-09 Ανοσογονικη συνθεση για clostridium difficile

Country Status (18)

Country Link
US (1) US20170218031A1 (el)
EP (2) EP3160500B1 (el)
JP (2) JP6688233B2 (el)
CN (1) CN106536544B (el)
BE (1) BE1022949B1 (el)
BR (1) BR112016030096B1 (el)
CA (1) CA2952118A1 (el)
CY (1) CY1122145T1 (el)
DK (1) DK3160500T3 (el)
ES (1) ES2749701T3 (el)
HR (1) HRP20191864T1 (el)
HU (1) HUE045936T2 (el)
LT (1) LT3160500T (el)
MX (1) MX2016017094A (el)
PL (1) PL3160500T3 (el)
PT (1) PT3160500T (el)
SI (1) SI3160500T1 (el)
WO (1) WO2015197737A1 (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3595709A4 (en) * 2017-03-15 2020-12-23 Novavax, Inc. METHODS AND COMPOSITIONS FOR INDUCING IMMUNE RESPONSES TO CLOSTRIDIUM DIFFICILE
CN112703006A (zh) 2018-06-19 2021-04-23 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
EP0362278A4 (en) 1987-06-05 1990-05-14 Us Health FACTORS OF AUTOCRINE MOTILITY IN THE DIAGNOSIS AND TREATMENT OF CANCER.
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ATE115862T1 (de) 1989-02-04 1995-01-15 Akzo Nobel Nv Tocole als impfstoffadjuvans.
PL170980B1 (pl) 1992-06-25 1997-02-28 Smithkline Beecham Biolog Szczepionka PL PL PL PL PL PL PL
ES2162139T5 (es) 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
NZ295998A (en) 1994-10-24 1999-10-28 Ophidian Pharm Inc Neutralizing antitoxins against clostridium difficile and clostidium botulinum toxins
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP0832282A1 (en) 1995-06-02 1998-04-01 Incyte Pharmaceuticals, Inc. IMPROVED METHOD FOR OBTAINING FULL-LENGTH cDNA SEQUENCES
JP2002542169A (ja) * 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン
US20020065396A1 (en) 2000-03-28 2002-05-30 Fei Yang Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
WO2005004791A2 (en) * 2002-11-08 2005-01-20 President And Fellows Of Harvard College Compounds and methods for the treatment and prevention of bacterial infection
AU2012349753A1 (en) * 2011-12-08 2014-06-19 Novartis Ag Clostridium difficile toxin-based vaccine
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
SI2928489T1 (sl) * 2012-12-05 2019-05-31 Glaxosmithkline Biologicals S.A. Imunogeni sestavek
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition

Also Published As

Publication number Publication date
BE1022949B1 (fr) 2016-10-21
JP6688233B2 (ja) 2020-04-28
CA2952118A1 (en) 2015-12-30
PL3160500T3 (pl) 2020-02-28
EP3160500A1 (en) 2017-05-03
BE1022949A1 (fr) 2016-10-21
ES2749701T3 (es) 2020-03-23
BR112016030096A2 (pt) 2017-08-22
EP3636278A2 (en) 2020-04-15
EP3160500B1 (en) 2019-08-21
MX2016017094A (es) 2017-05-03
WO2015197737A1 (en) 2015-12-30
US20170218031A1 (en) 2017-08-03
LT3160500T (lt) 2019-10-25
HRP20191864T1 (hr) 2020-01-10
JP2020100625A (ja) 2020-07-02
PT3160500T (pt) 2019-11-11
CN106536544A (zh) 2017-03-22
CN106536544B (zh) 2020-04-07
JP2017520573A (ja) 2017-07-27
BR112016030096A8 (pt) 2021-07-06
EP3636278A3 (en) 2020-07-15
DK3160500T3 (da) 2019-11-11
HUE045936T2 (hu) 2020-01-28
SI3160500T1 (sl) 2019-11-29
BR112016030096B1 (pt) 2023-10-03

Similar Documents

Publication Publication Date Title
CY1124106T1 (el) Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων
CO2018011804A2 (es) Receptores quiméricos de flt3 y métodos de uso de los mismos
CY1122898T1 (el) Απεκκριση πολυπεπτιδιων που περιεχουν αιμη
DOP2021000022A (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
CY1124619T1 (el) Αντισωματα αντι-προ/λανθανουσας μυοστατινης και χρησεις αυτων
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
CY1121535T1 (el) Πρωτεϊνικα κατασκευασματα uspa2 και χρησεις αυτων
BR112018005779A2 (pt) repressores de htt e usos dos mesmos
CL2018000042A1 (es) Anticuerpos de unión a tau
CL2016002733A1 (es) Combinación de lenalidomida y constructo de polipéptido, y sus usos
TR201906843T4 (tr) Hızlı etkili insülin bileşimleri.
BR112016028891A2 (pt) processos de trens de sementes e usos dos mesmos
BR112017011932A2 (pt) ?anticorpos direcionados a receptor acoplado a proteína g e métodos de uso?
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
EP3155018A4 (en) Constant region antibody fusion proteins and compositions thereof
BR112016022658A2 (pt) anticorpos anti-ox40 e métodos de uso
CY1122145T1 (el) Ανοσογονικη συνθεση για clostridium difficile
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης
GT201700131A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
CL2018000043A1 (es) Anticuerpos de unión a tau
EA201692002A1 (ru) Стабильные составы для антител к cd19 и конъюгатов антитело-лекарственное средство
MD3215187T2 (ro) Vaccinuri HPV16 terapeutice
EA201891460A1 (ru) Композиция дендритных клеток
CY1122644T1 (el) Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων
BR112015025748A2 (pt) construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna